— Presentations to be webcast on www.exelixis.com —Exelixis, Inc. (NASDAQ:EXEL) today announced that company management will participate in fireside chats at the following investor conferences in November:Guggenheim 3rd
– Total Revenues of $658.7 million, Cabozantinib Franchise U.S. Net Product Revenues of $604.9 million –
– GAAP Diluted EPS of $0.85, Non-GAAP Diluted EPS of $0.94 –
– Conference Call and Webcast Today at 5:00 PM
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT –
Exelixis, Inc. (NASDAQ:EXEL) announced today that its third quarter 2026 financial results will be released on Thursday, October 29, 2026,
SAN DIEGO, Oct. 14, 2026 /CNW/ -- Equity Insider News Commentary - Global spending on cancer medicines reached $252 billion in 2024 and is forecast to exceed $400 billion by 2028, according to the IQVIA Institute, with
NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of EXELIXIS, Inc. (NASDAQ: EXEL) breached their fiduciary duties to
– Presentations to be webcast on www.exelixis.com –
Exelixis, Inc. (NASDAQ:EXEL) today announced that company management will participate in fireside chats at the following investor conferences in September:
Wells
Exelixis, Inc. (NASDAQ:EXEL) today announced that in the lawsuit Exelixis, Inc. (Exelixis) vs. MSN Laboratories Private Limited et al. (MSN), Civil Action No. 22-00228 (Consolidated), the U.S. Court of Appeals for the
NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of EXELIXIS, Inc. (NASDAQ: EXEL) breached their fiduciary duties to
Exelixis posted second-quarter revenue of approximately $628.7 million -- short of Wall Street consensus -- and shares sold off in after-hours trading. Levi & Korsinsky is investigating. NEW YORK, Aug. 17, 2026
Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Exelixis, Inc. ("Exelixis" or "the
NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Shareholders of Exelixis, Inc. (NASDAQ:EXEL) watched the stock decline in after-hours trading following the Company's second quarter results, in which adjusted earnings
Exelixis shares fell after the Company reported Q2 revenue of approximately $628.7 million -- below Wall Street consensus -- and lowered its full-year 2026 revenue guidance, citing a slower-than-expected
Exelixis lowered and narrowed its full-year 2026 revenue guidance, citing a slower-than-expected neuroendocrine-tumor ramp -- and shares declined. SueWallSt notifies investors of a pending investigation into potential
On May 5, 2026, Exelixis management reiterated full-year 2026 financial guidance. Weeks later, the Company lowered and narrowed that revenue outlook -- and the stock fell. NEW YORK, Aug. 10, 2026 /PRNewswire/ --
- Total Revenues of $628.7 million, Cabozantinib Franchise U.S. Net Product Revenues of $573.0 million -
- GAAP Diluted EPS of $0.82, Non-GAAP Diluted EPS of $0.91 -
- Conference Call and Webcast Today at 5:00 PM
